Advanced biomaterials for diabetes healthcare and complication therapy: A review
Source abstract
Abstract
With the rapid increase in the number of patients with diabetes, exploring more effective and convenient methods to lower blood sugar levels is becoming increasingly important. Biomaterials are a potential solution in this field, owing to their unique customizability and biocompatibility. These materials can be used in smart drug delivery systems to achieve precise control of insulin release, or as islet cell encapsulation materials to achieve effective transplantation of islet cells. Among these, new responsive biomaterials can automatically adjust the release of insulin according to real-time changes in blood sugar levels, thereby enabling personalized and automated treatment. In addition, biomaterials are used to develop noninvasive blood glucose monitoring technologies to further simplify diabetes management. Although these applications are still in the research or early pilot stage, their potential to improve diabetes treatment and the quality of life of patients is already evident. In this Review, we discuss the current progress, limitations, and potential of biomaterials for the treatment of diabetes and its complications.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Pancreatic function and diabetes · Advanced Drug Delivery Systems · Diabetes Management and Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Medical Laboratory, Clinical Medical College/Affiliated Hospital of Jiujiang University 1 , Jiujiang, Jiangxi,
Jiujiang Clinical Precision Medicine Research Center 2 , Jiujiang, Jiangxi,
Funding
Jiangxi Province Traditional Chinese Medicine Science and Technology Plan
References (100+)
Show source-provided references
1. Macrophage polarization and diabetic wound healing10.1016/j.trsl.2021.05.006 ↗
2. Diabetes: A 21st century challenge10.1016/s2213-8587(13)70112-8 ↗
3. IDF diabetes atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 204510.1016/j.diabres.2021.109119 ↗
4. Current understanding of the molecular and cellular pathology of diabetic retinopathy10.1038/s41574-020-00451-4 ↗
5. Definitions and criteria for diabetic foot disease10.1002/dmrr.3268 ↗
6. Mechanisms of diabetic complications10.1152/physrev.00045.2011 ↗
7. Screening for diabetic retinopathy: New perspectives and challenges10.1016/s2213-8587(19)30411-5 ↗
8. Biomaterial-mediated strategies for accurate and convenient diagnosis, and effective treatment of diabetes: Advantages, current progress and future perspectives10.1039/d3tb00034f ↗
9. Inspiration and application in the evolution of biomaterials10.1038/nature08601 ↗
10. Development and evaluation of resveratrol-loaded liposomes in hydrogel-based wound dressing for diabetic foot ulcer10.1007/s00210-023-02441-5 ↗
11. pH-sensitive peptide hydrogel for glucose-responsive insulin delivery10.1016/j.actbio.2017.01.016 ↗
12. Zinc insulin hexamer loaded alginate zinc hydrogel: Preparation, characterization and in vivo hypoglycemic ability10.1016/j.ejpb.2022.08.016 ↗
13. Effective enhancement of hypoglycemic effect of insulin by liver-targeted nanoparticles containing cholic acid-modified chitosan derivative10.1021/acs.molpharmaceut.6b00188 ↗
14. Intranasal repaglinide-solid lipid nanoparticles integrated in situ gel outperform conventional oral route in hypoglycemic activity10.1016/j.jddst.2021.103086 ↗
15. Dissolving microneedles for transdermal drug delivery10.1016/j.biomaterials.2007.12.048 ↗
16. Coated microneedles for transdermal delivery10.1016/j.jconrel.2006.10.017 ↗
17. Supercritical fluid-assisted porous microspheres for efficient delivery of insulin and inhalation therapy of diabetes10.1002/adhm.201800910 ↗
18. Highly porous large poly(lactic-co-glycolic acid) microspheres adsorbed with palmityl-acylated exendin-4 as a long-acting inhalation system for treating diabetes10.1016/j.biomaterials.2010.10.045 ↗
19. Drug delivery system in the treatment of diabetes mellitus10.3389/fbioe.2020.00880 ↗
20. 30–Nanoengineered biomaterials for diabetes
21. The changing face of diabetes complications10.1016/s2213-8587(16)30010-9 ↗
22. Diabetic neuropathy: What does the future hold?10.1007/s00125-020-05085-9 ↗
23. Classification, differential diagnosis, and staging of diabetic peripheral neuropathy10.2337/diab.46.2.s54 ↗
24. Diabetic neuropathy10.1038/s41572-019-0092-1 ↗
25. Painful and non-painful diabetic neuropathy, diagnostic challenges and implications for future management10.1093/brain/awab079 ↗
26. Diabetic neuropathy and neuropathic pain: A (con)fusion of pathogenic mechanisms?10.1097/j.pain.0000000000001922 ↗
27. Understanding diabetic neuropathy: Focus on oxidative stress10.1155/2020/9524635 ↗
28. Diabetic neuropathy: New perspectives on early diagnosis and treatments10.52845/JCDR/2020v1i1a3 ↗
29. New horizons of biomaterials in treatment of nerve damage in diabetes mellitus: A translational prospective review10.3389/fendo.2022.1036220 ↗
30. The role of inflammation in diabetic retinopathy10.3389/fimmu.2020.583687 ↗
31. Oxidative stress and diabetic retinopathy: Molecular mechanisms, pathogenetic role and therapeutic implications10.1016/j.redox.2020.101799 ↗
32. Global prevalence of diabetic retinopathy and projection of burden through 2045: Systematic review and meta-analysis10.1016/j.ophtha.2021.04.027 ↗
33. The evolving treatment of diabetic retinopathy10.2147/opth.s236637 ↗
34. Diabetes mellitus, glycemic traits, and cerebrovascular disease: A Mendelian randomization study10.1212/wnl.0000000000011555 ↗
35. Hypoglycemic and hyperglycemic crises among U.S. adults with diabetes and end-stage kidney disease: Population-based study, 2013–201710.2337/dc21-1579 ↗
36. Diabetes and ischemic stroke: An old and new relationship an overview of the close interaction between these diseases10.3390/ijms23042397 ↗
37. Macrovascular complications of type 2 diabetes mellitus10.2174/1570161117666190405165151 ↗
38. Cerebrovascular complications of diabetes: SGLT-2 inhibitors as a promising future therapeutics10.2174/1389450121666201020163454 ↗
39. Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with type 2 diabetes mellitus with or without established cardiovascular disease: A meta-analysis of randomized controlled trials10.1093/eurheartj/ehaa082 ↗
40. Managing diabetic foot ulcers: Pharmacotherapy for wound healing10.1007/s40265-020-01415-8 ↗
41. The current burden of diabetic foot disease10.1016/j.jcot.2021.01.017 ↗
42. Strategy for treatment of infected diabetic foot ulcers10.1021/acs.accounts.0c00864 ↗
43. Hyperglycemia
44. Guidelines on the classification of diabetic foot ulcers (IWGDF 2019)10.1002/dmrr.3273 ↗
45. Current therapeutic strategies in diabetic foot ulcers10.3390/medicina55110714 ↗
46. Clinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management10.1016/j.apsb.2020.12.020 ↗
47. Novel glucose-responsive nanoparticles based on p-hydroxyphenethyl anisate and 3-acrylamidophenylboronic acid reduce blood glucose and ameliorate diabetic nephropathy10.1016/j.mtbio.2021.100181 ↗
48. Pathogenetic mechanisms of diabetic nephropathy10.1681/asn.2004110970 ↗
49. Therapeutic advances in diabetic nephropathy10.3390/jcm11020378 ↗
50. Diabetic nephropathy: Diagnosis, prevention, and treatment10.2337/diacare.28.1.164 ↗
51. Diabetic nephropathy: An overview
52. Advances of hydrogel dressings in diabetic wounds10.1039/d0bm01747g ↗
53. Diabetic wound-healing science10.3390/medicina57101072 ↗
54. Advanced bandages for diabetic wound healing10.1126/scitranslmed.abe4839 ↗
55. Mechanistic insight into diabetic wounds: Pathogenesis, molecular targets and treatment strategies to pace wound healing10.1016/j.biopha.2019.108615 ↗
56. ROS-scavenging hydrogel to promote healing of bacteria infected diabetic wounds10.1016/j.biomaterials.2020.120286 ↗
57. The role of oxidative stress and antioxidants in diabetic wound healing10.1155/2021/8852759 ↗
58. A strain-programmed patch for the healing of diabetic wounds10.1038/s41551-022-00905-2 ↗
59. Conductive biomaterials as bioactive wound dressing for wound healing and skin tissue engineering10.1007/s40820-021-00751-y ↗
60. Acetone gas sensor based on NiO/ZnO hollow spheres: Fast response and recovery, and low (ppb) detection limit10.1016/j.jcis.2017.01.106 ↗
61. Intensive glycemic control and cardiovascular disease: An update10.1038/nrcardio.2010.35 ↗
62. Preventing diabetic retinopathy progression10.1016/j.ophtha.2016.05.039 ↗
63. Continuous glucose monitoring: A review of the evidence in type 1 and 2 diabetes mellitus10.1111/dme.14528 ↗
64. Continuous glucose monitoring10.1136/bmj-2022-072420 ↗
65. Randomized trial of closed-loop control in very young children with type 1 diabetes10.1056/nejmoa2111673 ↗
66. A randomized trial of closed-loop control in children with type 1 diabetes10.1056/nejmoa2004736 ↗
67. Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes10.1056/nejmoa1907863 ↗
68. Evolution of insulin delivery devices: From syringes, pens, and pumps to DIY artificial pancreas10.1007/s13300-020-00831-z ↗
69. Facile synthesis of semi-library of low charge density cationic polyesters from poly(alkylene maleate)s for efficient local gene delivery10.1016/j.biomaterials.2018.03.050 ↗
70. Evolution of insulin: From human to analog10.1016/j.amjmed.2014.07.005 ↗
71. A review of phenformin, metformin, and imeglimin10.1002/ddr.21636 ↗
72. Insulin-from its discovery to the industrial synthesis of modern insulin analogues10.1002/anie.201702493 ↗
73. Nateglinide, a non-sulfonylurea rapid insulin secretagogue, increases pancreatic islet blood flow in rats10.1016/j.ejphar.2005.05.044 ↗
74. Synthesis and antihyperglycemic activity profiles of novel thiazolidinedione derivatives10.1016/j.bmc.2004.08.031 ↗
75. Synthesis and blood glucose lowering activity of novel benzenesulfonyl-urea derivatives10.1080/10426500802467187 ↗
76. Topical gel-based biomaterials for the treatment of diabetic foot ulcers10.1016/j.actbio.2021.10.045 ↗
77. Bioinspired pH-responsive microalgal hydrogels for oral insulin delivery with both hypoglycemic and insulin sensitizing effects10.1021/acsnano.3c04897 ↗
78. Glucose-responsive multifunctional metal-organic drug-loaded hydrogel for diabetic wound healing10.1016/j.actbio.2021.11.043 ↗
79. Hydrogels in emerging technologies for type 1 diabetes10.1021/acs.chemrev.0c01062 ↗
80. Recent advancement of functional hydrogels toward diabetic wound management10.1021/acsomega.2c05538 ↗
81. Recent advances in responsive hydrogels for diabetic wound healing10.1016/j.mtbio.2022.100508 ↗
82. Developing robust, hydrogel-based, nanofiber-enabled encapsulation devices (NEEDs) for cell therapies10.1016/j.biomaterials.2014.10.032 ↗
83. Current understanding of hydrogel for drug release and tissue engineering10.3390/gels8050301 ↗
84. Microneedles for transdermal drug delivery10.1016/j.addr.2003.10.023 ↗
85. Smart microneedles for therapy and diagnosis10.34133/2020/7462915 ↗
86. Microneedles for painless transdermal immunotherapeutic applications10.1016/j.jconrel.2020.12.019 ↗
87. Microneedles for drug and vaccine delivery10.1016/j.addr.2012.04.005 ↗
88. Microfabricated microneedles for gene and drug delivery10.1146/annurev.bioeng.2.1.289 ↗
89. Glucose-responsive microneedle patch for closed-loop dual-hormone delivery in mice and pigs10.1126/sciadv.add3197 ↗
90. Nanoparticles in the clinic10.1002/btm2.10003 ↗
91. Advances in oral peptide drug nanoparticles for diabetes mellitus treatment10.1016/j.bioactmat.2022.02.025 ↗
92. Glucose-responsive oral insulin delivery for postprandial glycemic regulation10.1007/s12274-018-2264-9 ↗
93. Encapsulation of curcumin nanoparticles with MMP9-responsive and thermos-sensitive hydrogel improves diabetic wound healing10.1021/acsami.8b03868 ↗
94. Magnetic biohybrid microspheres for protein purification and chronic wound healing in diabetic mice10.1016/j.cej.2021.130671 ↗
95. ROS-responsive microspheres for on demand antioxidant therapy in a model of diabetic peripheral arterial disease10.1016/j.biomaterials.2014.11.016 ↗
96. Microspheres for biomedical applications: Preparation of reactive and labelled microspheres10.1016/0142-9612(93)90015-t ↗
97. Biodegradable microspheres for protein delivery10.1016/s0168-3659(03)00194-9 ↗
98. Biologically erodable microspheres as potential oral drug delivery systems10.1038/386410a0 ↗
99. Application of biomedical microspheres in wound healing10.3390/ijms24087319 ↗
100. Glucose induced permeation control of insulin through a complex membrane consisting of immobilized glucose oxidase and a poly(amine)10.1295/polymj.16.625 ↗